← Leaderboards
Jia Wu
Stanford University
$3,637,726
Attributed
$6,206,749
Total exposure
4
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$6,206,749 · 4
By mechanism
R01$5,138,046 · 2
R00$746,999 · 1
K99$321,704 · 1
Top collaborators
- Tina Cascone5 shared
- Natalie Vokes3 shared
Most similar at Stanford University
Same institution · by research overlap
- Ruijiang Li$10,760,802
- Brian Andrew Hargreaves$16,291,706
- Bruce L Daniel$13,717,379
- Dwight G Nishimura$12,073,587
- Julia Ann Kornfield$917,463
Others in their field
Other Emerging Leaders on “Tumor”
- Leonard Freedman · Leidos Biomedical Research, Inc.$360,535,780
- Lynn Briscoe · Leidos Biomedical Research, Inc.$120,794,323
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$105,180,681
- Leonard Freedmand · Leidos Biomedical Research, Inc.$78,762,245
- Connie Suders · Leidos Biomedical Research, Inc.$67,882,919
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
Research focus
TumorTreatment ResponseClinically RelevantMalignant NeoplasmsPhenotypeCohortBiological MarkersBiologicalImageImaging BiomarkerResponseQuantitative ImagingAdjuvant TherapyMolecular MarkerPersonalized ManagementNeoadjuvant TherapyPathologicCharacteristicsAdjuvantMortalityComputerized ToolsAlgorithmsLeadMultiple Omics
Grant awards (13)
Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer$665,352
R01 · FY2025 · CA
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer$606,797
R01 · FY2025 · CA · contact PI
Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer$636,160
R01 · FY2024 · CA
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer$609,048
R01 · FY2024 · CA · contact PI
Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer$676,561
R01 · FY2023 · CA
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer$658,205
R01 · FY2023 · CA · contact PI
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer$661,394
R01 · FY2022 · CA · contact PI
QUANTITATIVE IMAGING BIOMARKERS OF TREATMENT RESPONSE AND PROGNOSIS IN BREAST CANCER$249,000
R00 · FY2022 · CA · contact PI
Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer$624,529
R01 · FY2021 · CA · contact PI
QUANTITATIVE IMAGING BIOMARKERS OF TREATMENT RESPONSE AND PROGNOSIS IN BREAST CANCER$249,000
R00 · FY2021 · CA · contact PI
QUANTITATIVE IMAGING BIOMARKERS OF TREATMENT RESPONSE AND PROGNOSIS IN BREAST CANCER$248,999
R00 · FY2020 · CA · contact PI
Quantitative Imaging Biomarkers of Treatment Response and Prognosis in Breast Cancer$160,852
K99 · FY2019 · CA · contact PI
Quantitative Imaging Biomarkers of Treatment Response and Prognosis in Breast Cancer$160,852
K99 · FY2018 · CA · contact PI